Common side effects reported with Melanotan II include: Nausea and vomiting Facial flushing Cardiovascular effects including potential blood pressure changes Spontaneous erections (priapism risk) Darkening of skin and moles Potential effects on existing moles or skin lesions Of particular concern is the risk of priapism a prolonged, painful erection lasting more than four hourswhich constitutes a medical emergency requiring immediate treatment to prevent permanent damage to penile tissue
Summary: Cagrilintide and retatrutide are investigational injectable medicines being studied for obesity and type 2 diabetes in men, targeting multiple hormonal pathways to reduce appetite, improve blood glucose control, and increase energy expenditure, but neither is currently licensed in the UK
Particular risks arise where a page contains: Human outcome promises Preparation or administration guidance Personal testimonials Before-and-after photographs Consumer starter packs Clinical-style product comparisons Statements encouraging self-experimentation Advertising an Unauthorised Medicinal Product Regulation 279 of the Human Medicines Regulations restricts publication of advertisements for medicinal products lacking the required authorisation, registration or certificate
Mental health literacy, folic acid and vitamin B12, and physical activity for the prevention of depression in older adults: randomised controlled trial
.jpg)
